Last $4.80 USD
Change Today -1.20 / -20.00%
Volume 6.0K
As of 8:10 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

restorgenex corp (RESX) Snapshot

Open
$4.75
Previous Close
$6.00
Day High
$5.00
Day Low
$4.60
52 Week High
05/6/13 - $24.00
52 Week Low
03/5/14 - $2.37
Market Cap
41.7M
Average Volume 10 Days
1.5K
EPS TTM
$5.10
Shares Outstanding
8.7M
EX-Date
--
P/E TM
0.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for RESTORGENEX CORP (RESX)

Related News

No related news articles were found.

restorgenex corp (RESX) Related Businessweek News

No Related Businessweek News Found

restorgenex corp (RESX) Details

RestorGenex Corporation operates as a specialty biopharmaceutical company that focuses on developing products for dermatology, ophthalmology, and women’s health. Its product under development includes HYG-102, a soft estrogen for the treatment of aging skin fragility/thinning; HYG-440, a soft anti-androgen for the treatment of androgen excess, e.g. acne, male-pattern baldness, and hirsutism; and P529, a prescription dermatology compound used for the treatment of keloid scarring, psoriasis, atopic dermatitis, rosacea, actinic keratosis, Dupuytren’s disease, and the bullous blistering diseases. RestorGenex Corporation has Collaboration Agreement with Ferndale Pharma Group, Inc. for developing aging skin product. The company was formerly known as Stratus Media Group, Inc. and changed its name to RestorGenex Corporation in March 2014. RestorGenex Corporation is based in Los Angeles, California.

restorgenex corp (RESX) Top Compensated Officers

Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $220.0K
Vice President of Legal Affairs and General C...
Total Annual Compensation: $180.0K
Compensation as of Fiscal Year 2013.

restorgenex corp (RESX) Key Developments

Restorgenex Corporation announced delayed annual 10-K filing

On 03/28/2014, Restorgenex Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.

RestorGenex Appoints Stephen M. Simes as Chief Executive Officer

RestorGenex announced that it has named Stephen M. Simes as its Chief Executive Officer, to lead the company. Mr. Simes formerly served as vice chairman, president, and CEO at BioSante Pharmaceuticals, Inc. Mr. Simes replaces Jerold Rubinstein who resigned as chief executive officer effective with Mr. Simes' appointment. Mr. Rubenstein remains a director and chairman of the Audit Committee.

Stratus Media Group, Inc. has Changed its Name to RestorGenex Corporation

On March 10, 2014, Stratus Media Group, Inc. changed its name to RestorGenex Corporation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RESX:US $4.80 USD -1.20

RESX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RESX.
View Industry Companies
 

Industry Analysis

RESX

Industry Average

Valuation RESX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 221.6x
Price/Book 5.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 697.3x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESTORGENEX CORP, please visit www.stratusmediagroup.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.